PT - JOURNAL ARTICLE AU - Singh, Samer AU - Maurya, Rajendra P. AU - Singh, Rakesh K. TI - ‘Trained immunity’ from <em>Mycobacterium spp.</em> exposure or BCG vaccination and COVID-19 outcomes AID - 10.1101/2020.07.11.20151308 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.11.20151308 4099 - http://medrxiv.org/content/early/2020/07/14/2020.07.11.20151308.short 4100 - http://medrxiv.org/content/early/2020/07/14/2020.07.11.20151308.full AB - Protective variables for COVID-19 are unknown. ‘Trained immunity’ of the populace as a result of mandatory BCG immunization policy implementation by countries has been suggested as one of the factors responsible for the differential impact of COVID-19 on different countries. Several trials are underway to evaluate the potential protective role of BCG vaccination in COVID-19. However, the lack of clarity on the use of appropriate controls concerning ‘trained immunity’ has been a cause of concern leading to more confusion as exemplified by a recently concluded trial in Israel that failed to find any correlation. Whereas, when we analyze the COVID-19 data of European countries without any mandatory BCG vaccination policy but with similar age distribution, comparable confounding variables, and the stage of the pandemic, the prevalence of Mycobacterium spp. (including BCG vaccine) exposure of the populations is consistently negatively correlated with COVID-19 infections per million population at all the time points evaluated [r(20): −0.5511 to −0.6338; p-value: 0.0118 to 0.0027]. The results indicate that the on-going and future studies evaluating the effect of BCG vaccination on COVID-19 outcomes should consider the inclusion of ‘controls’ for underlying ‘trained immunity’ prevalence or that resulting from the intervention (BCG vaccine) in such trials to arrive at more dependable conclusions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo specific funding received for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred in the manuscript are included in the manuscript.